Cost-effectiveness analysis of germline brca mutation testing and olaparib treatment in metastatic breast cancer: An evaluation of codependent technologies

Abstract

Genetic testing for a germline BRCA mutation in women with HER2-negative metastatic breast cancer (MBC) can guide targeted treatment with PARP inhibitors (e.g. olaparib) and inform cancer prevention strategies (e.g., risk-reducing surgery) for family members of women who test positive. Unlike BRCA testing in localised breast cancer, the cost-effectiveness of genetic testing in MBC is unknown. This study aimed to evaluate the cost-effectiveness of BRCA testing in women with MBC to guide olaparib treatment.